Company Product Description Indication Status
Eisai Co. Ltd., of Tokyo Lenvima (lenvatinib mesylate) Multikinase inhibitor Uterine body cancer Japan’s MHLW granted orphan designation
Johnson & Johnson, of New Brunswick, N.J. Single-dose COVID-19 vaccine SARS-CoV-2 recombinant adenoviral vector vaccine COVID-19 European Commission granted conditional marketing authorization, valid in all 27 member states of EU, plus Norway, Iceland and Liechtenstein; World Health Organization also issued emergency use listing for vaccine to prevent COVID-19 in adults, 18 and older
Russian Direct Investment Fund, of Moscow Sputnik V  COVID-19 spike glycoprotein modulator COVID-19 Vaccine approved by Ministry of Health of the Republic of Azerbaijan
Sanofi SA, of Paris Fabrazyme (agalsidase beta) Alpha-galactosidase stimulator Fabry disease Results from real-world observational study and clinical trial on long-term treatment now included in FDA-approved label
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan Lanadelumab Monoclonal antibody targeting plasma kallikrein  Hereditary angioedema Submitted NDA to Japan’s MHLW seeking approval for prophylaxis against HAE attacks

Notes

For more information about individual companies and/or products, see Cortellis.